Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.39 Million CNY | -127.44% |
| 2022 | -2.95 Million CNY | 22.34% |
| 2021 | -3.8 Million CNY | 56.52% |
| 2020 | -8.74 Million CNY | -1960.0% |
| 2019 | 470 Thousand CNY | -81.94% |
| 2018 | 2.6 Million CNY | 1448.7% |
| 2017 | -193 Thousand CNY | -101.7% |
| 2016 | 11.36 Million CNY | 8.4% |
| 2015 | 10.48 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.28 Million CNY | 61.14% |
| 2024 Q2 | -1.28 Million CNY | 0.0% |
| 2023 Q2 | -933 Thousand CNY | -106.87% |
| 2023 Q4 | -3.3 Million CNY | -307.27% |
| 2023 Q1 | -451 Thousand CNY | 84.16% |
| 2023 Q3 | -811 Thousand CNY | 13.08% |
| 2023 FY | -6.71 Million CNY | -127.44% |
| 2022 Q2 | -847 Thousand CNY | -26.42% |
| 2022 Q1 | -670 Thousand CNY | 71.77% |
| 2022 FY | -2.95 Million CNY | 22.34% |
| 2022 Q3 | 196 Thousand CNY | 123.14% |
| 2022 Q4 | -2.84 Million CNY | -1552.55% |
| 2021 Q4 | -2.37 Million CNY | -972.43% |
| 2021 FY | -3.8 Million CNY | 56.52% |
| 2021 Q3 | 272 Thousand CNY | 153.75% |
| 2021 Q2 | -506 Thousand CNY | 56.86% |
| 2021 Q1 | -1.17 Million CNY | 51.04% |
| 2020 Q4 | -2.39 Million CNY | -740.64% |
| 2020 Q3 | 374 Thousand CNY | 111.45% |
| 2020 Q2 | -3.26 Million CNY | -27.53% |
| 2020 Q1 | -2.56 Million CNY | -89.7% |
| 2020 FY | -8.74 Million CNY | -1960.0% |
| 2019 Q4 | -1.35 Million CNY | -255.71% |
| 2019 Q3 | 867 Thousand CNY | 360.75% |
| 2019 Q2 | -332.5 Thousand CNY | 74.72% |
| 2019 FY | 470 Thousand CNY | -81.94% |
| 2019 Q1 | -1.31 Million CNY | 43.88% |
| 2018 Q3 | 2.4 Million CNY | 22.34% |
| 2018 Q4 | -2.34 Million CNY | -197.54% |
| 2018 FY | 2.6 Million CNY | 1448.7% |
| 2018 Q2 | 1.96 Million CNY | 590.14% |
| 2018 Q1 | -400.75 Thousand CNY | 0.0% |
| 2017 FY | -193 Thousand CNY | -101.7% |
| 2016 FY | 11.36 Million CNY | 8.4% |
| 2015 FY | 10.48 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 105.168% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.278% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 9.446% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 118.08% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 85.836% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 120.507% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 102.382% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 88.809% |
| SSY Group Limited | 1.63 Billion HKD | 100.451% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 104.243% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 102.219% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.061% |